<?xml version="1.0" encoding="UTF-8"?>
<p class="p">In the present work, we also evaluated the anti-AChE and anti-BChE activities (
 <xref ref-type="table" rid="pharmaceuticals-10-00084-t004" class="xref">Table 4</xref>). Acorenone B showed an inhibitory activity against AChE and BChE with IC
 <sub xmlns="http://www.w3.org/1999/xhtml">50</sub> concentrations of 40.8 and 10.9 μg/mL, respectively (
 <xref ref-type="fig" rid="pharmaceuticals-10-00084-f004" class="xref">Figure 4</xref>). These inhibitory potentials, even far from that of the reference compound donepezil (6.7 nM) versus AChE [
 <xref rid="B38-pharmaceuticals-10-00084" ref-type="bibr" class="xref">38</xref>], are close to those previously published for galanthamine (2.2 µg/mL and 11.7 µg/mL) or other plant extracts [
 <xref rid="B4-pharmaceuticals-10-00084" ref-type="bibr" class="xref">4</xref>,
 <xref rid="B39-pharmaceuticals-10-00084" ref-type="bibr" class="xref">39</xref>,
 <xref rid="B40-pharmaceuticals-10-00084" ref-type="bibr" class="xref">40</xref>]. Interestingly, in spite of its moderate inhibitory potential, galanthamine is a typical drug used for the treatment of Alzheimer's disease [
 <xref rid="B41-pharmaceuticals-10-00084" ref-type="bibr" class="xref">41</xref>], validating our efforts to identify new potential inhibitory compounds. 
 <italic class="italic">Niphogeton dissecta</italic> essential oil exhibited selectivity for the inhibition of BChE, this property being particularly interesting in the treatment of Alzheimer's disease [
 <xref rid="B40-pharmaceuticals-10-00084" ref-type="bibr" class="xref">40</xref>,
 <xref rid="B42-pharmaceuticals-10-00084" ref-type="bibr" class="xref">42</xref>].
</p>
